Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials (Q33836604)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

circulatory system

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

object named as

Giusi Graziano

3

0 references

Giorgio Gentile

object named as

Giorgio Gentile

17

0 references

object named as

Vlado Perkovic

10

0 references

Salvatore De Cosmo

object named as

Salvatore De Cosmo

12

0 references

object named as

David Johnson

5

0 references

object named as

Jonathan C Craig

8

0 references

Giovanni Strippoli

18

object named as

Giovanni F M Strippoli

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sankar Navaneethan

2

object named as

Sankar D Navaneethan

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

object named as

Ausilia Maione

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Giovanni Tognoni

9

object named as

Giovanni Tognoni

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

13

object named as

Antonio Sasso

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

14

object named as

Olga Lamacchia

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Mauro Cignarelli

15

object named as

Mauro Cignarelli

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Valeria Maria Manfreda

16

object named as

Valeria Maria Manfreda

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Ruth Mitchell

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Johannes F E Mann

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Peggy Gao

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Antonio Nicolucci

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

3 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Nephrology Dialysis Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2827-2847

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Prevalence of chronic kidney disease in the United States

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Survival in patients with type 2 diabetes in a Swedish community: skaraborg hypertension and diabetes project

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Rationale for double renin-angiotensin-aldosterone system blockade

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Efficacy and safety of benazepril for advanced chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM).

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Efficacy of valsartan in the therapy of persistent microalbuminuria in normotensive patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Is losartan as effective as enalapril on posttransplant persistent proteinuria?

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

The effects of losartan and fosinopril in hypertensive type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Differing anti-proteinuric action of candesartan and losartan in chronic renal disease

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Combining GFR and albuminuria to classify CKD improves prediction of ESRD.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Lowering blood pressure reduces renal events in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ792

21 January 2018

Identifiers

10.1093/NDT/GFQ792

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33836604&oldid=1747681107"